Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson's disease

Fig. 2

Reported AM fasting beta-hydroxybutyrate (BHB) mean values ± SEMs, days 1–7 (inpatient) and at week 3 (outpatient), by group. Day 1: baseline testing on regular diet; Days 2-7: inpatient randomized diet phase-ketogenic diet vs standard diet; Week 3: Assessment after 2 weeks of outpatient open-label ketogenic diet. Top: Total 7 subjects in the KD group vs. 9 subjects in the SD group; Middle: 3 subjects in the KD group vs. 7 subjects in the SD group without metabolic syndrome/insulin resistance; Bottom: 4 subjects in the KD group vs. 2 subjects in the SD group with metabolic syndrome/insulin resistance

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us